Facebook-f X-twitter Linkedin-in Instagram Podcast

News

Join Team TOGA at City2Surf 2025

Team TOGA is gearing up once again for the Sun Herald City2Surf.

Join the team to run or walk Sydney’s iconic 14km course from the CBD to Bondi Beach on Sunday 10 August 2025.  

Help TOGA raise funding for lung cancer and mesothelioma research and awareness for clinical trials saving lives. With less than 6% of cancer research funding allocated to lung cancer, every dollar raised will go towards supporting clinical research activities to diagnose, treat, and support people with lung cancer and mesothelioma. 

How to join Team TOGA

If you haven’t registered for the City2Surf:

  • Register here via the ‘Register Now’. This will register you for the City2Surf event.

Once you have registered for the City2Surf:

  • Click Start Fundraising: This will allow you to create your fundraising page. Once complete you can begin your fundraising efforts by sharing your goals with your friends, family, and network. 
Donate Now

Share this

Facebook
Twitter
LinkedIn
A flowchart detailing the ASPiRATION 2-Liquid study design. The study is an observational cohort of 500 adults with metastatic NSCLC, who have disease progression on targeted therapy and an ECOG performance status of 0-2. After consenting to screening, participants undergo both liquid biopsy and, if a biopsy was performed, tissue NGS.
ASPiRATION 2L: Liquid Biopsy Clinical Trial for Advanced Lung Cancer Patients Across Australia
Everything you need to know about the Australia-wide trial using liquid biopsy to guide treatment after targeted therapy progression in advanced lung cancer
Diagram summarising the DEFIANT phase 2 clinical trial evaluating datopotamab deruxtecan (Dato-DXd) in metastatic EGFR exon 20 insertion non-small cell lung cancer.
DEFIANT: A new clinical trial for EGFR exon20 insertion lung cancer
The DEFIANT trial will evaluate datopotamab deruxtecan (Dato-DXd) in EGFR exon 20 insertion NSCLC after targeted therapy and chemotherapy.
TOGA Annual Scientific Meeting 2026: Key Advances in Lung Cancer Care, Research and Screening
Discover the major advances from TOGA ASM 2026, including lung cancer screening, precision medicine, immunotherapy, survivorship and multidisciplinary care shaping the future of thoracic oncology.
Memorial tribute graphic featuring Professor Robert Stirling OAM speaking at a TOGA conference. The image includes the heading "Remembering Prof Robert Stirling OAM" and the words "A respected clinician, leader, educator and innovator whose vision has improved lung cancer care across Australia and around the world." The design uses a subdued blue colour palette to honour his legacy.
Remembering Professor Robert Stirling OAM
Professor Robert Stirling OAM devoted his career to improving the lives of people with lung cancer through clinical excellence, research, education and compassionate leadership.
Specialist Lung Cancer Nurse reviewing a lung cancer information brochure with an older patient during a consultation.
Why Every Service Needs a Specialist Lung Cancer Nurse
Their work is often invisible, but its impact isn't. Specialist Lung Cancer Nurses are quietly becoming the backbone of modern lung cancer care.
Mobilising teletrials
Teletrials, also known as digi trials, are when a clinician at a primary site uses telehealth (videoconference or telephone calls) to enrol, consent, treat and/or
A flow chart showing risk categories assigned to lung CT findings and the follow up pathways based on that risk.
What Happens After a Lung CT scan?
A simple guide to what happens after a lung CT scan in the Australian National Lung Cancer Screening Program
Dr Mark Adams, Dr Sagun Parakh, A/Prof Venessa Chin
Progress and Breakthroughs: An Update on the 2025 Inspirational Research Grant Recipients
Updates from our Inspirational Research Grant 2025 recipients on pioneering lung microbiome research and its impact on immunotherapy efficacy.
Optimal timeframes from lung cancer diagnosis to referral to treatment decision to commencement of treatment
Improving Timeliness in the Lung Cancer Optimal Care Pathway: Workshop Outcomes
Clinicians, nurses, consumers and health service leaders came together at TOGA’s Lung Cancer Optimal Care Pathway workshop to examine why Australia continues to struggle to
2026 Melbourne Nike Marathon Festival Run/Walk
October 11, 2026
On October 11, take part in the 2026 Nike Marathon Festival to run/walk the iconic route and finish in the MCG. Don’t miss out on
Donate Now
Be Part of Team TOGA at City2Surf 2026
August 9, 2026
Join the team to run or walk Sydney’s iconic 14km course from the CBD to Bondi Beach on Sunday 9 August 2026.
Donate Now
Clinical Trial Design Series: Glossary of Clinical Trial Terms and Acronyms in Cancer Research
Understanding the language helps patients, families and clinicians stay informed, confident and part of the conversation.
TOGA’s Scientific Committee Appointments
TOGA is pleased to announce the latest appoints for our Scientific Committee.
Celebrating Success: Over $50,000 Raised at the Lunar New Year Banquet
Discover how a vibrant Lunar New Year Banquet, organised by Dr. Angeline Low and Ms. Maria Chan, raised over $50,000 for vital lung cancer research.
Why Australia’s Medical Research Funding Must Be Released Now
The MRFF is holding $1B+ in unspent funds. Learn why TOGA is calling for the release of this research funding to accelerate lung cancer breakthroughs
Driving Innovation and Excellence: TOGA’s 2025 Annual Report
Discover TOGA’s FY25 highlights, including the new Strategic Plan, clinical trial milestones and record membership growth across Australia and New Zealand.
Text of Preventative and Quality Care Working Group
The Newest Working Group: Preventative and Quality Care
The Preventative and Quality Care Working Group represents TOGA’s commitment to improving the outcomes of thoracic cancers.
Aligning TOGA’s Working Groups with the Future of Thoracic Cancer Research
TOGA’s Working Groups are evolving to better reflect where thoracic cancer research is heading: From prevention and early detection through to advanced disease and living
Clinical Trial Design Series: Turning a Concept into a Clinical Trial
Learn how to turn your endorsed research concept into a clinical trial; from sponsor selection to budgeting, data, safety and protocol design.
Clinical trial design concept showing hypothesis to endpoint planning and sample size calculation on a chalkboard with a glowing lightbulb representing a research idea.
Clinical Trial Design Series: Getting Started with Investigator-Initiated Trials
Learn how to design an investigator-initiated clinical trial, from refining your research idea to securing TOGA endorsement and funding.
Understanding EGFR-Positive Lung Cancer: Why Prevalence is Higher in Asian Populations
Learn why EGFR-positive lung cancer disproportionately affects Asian populations and non-smokers. Discover modern targeted therapies and symptoms to watch for.
Lung Cancer in 2025: Key Advances in Screening, Diagnosis and Treatment in Australia
Discover how 2025 transformed lung cancer care in Australia. Explore the impact of national screening, modern diagnostics, and new PBS treatment approvals.
2025 Podcasts: Year in Review
Let's take a moment to celebrate the incredible guests, ground breaking discussions, and dedicated listeners that made 2025 our most successful year yet.
New Committee Positions Open
If you are interested in joining TOGA on a Committee, please submit your nominations by 30 January 2026
Scientific Committee Meeting with pen and notepad
TOGA’s Scientific Committee Meeting Recap – November 2025
The final Scientific Meeting of 2025 was held in November. Five concepts were presented, spanning both Recurrent and Metastatic NSCLC populations and four Mesothelioma concepts.
Bispecific antibodies mechanism of T cell activation
Bispecific Antibodies in Lung Cancer: Dual Targeting for a New Era of Treatment
Bispecific antibodies target two pathways at once, reshaping lung cancer treatment through dual checkpoint blockade and targeted precision.
A continuous circular flow showing the role of lung cancer advocacy in the relationship between research, clinical evidence (clinical trials), research translation and the equitable patient access. The centre of the circle lists words Innovation Evidence Equity
Lung Cancer Advocacy: From clinical trials to equitable care
Research advances only improve outcomes when they are accessible to patients. TOGA drives change in lung cancer care by advocating through stakeholder submissions, including PBS.......
Lunar New Year Banquet 2026
Join the Rotary Club of Chatswood International and lung cancer survivor Dr Angeline Low in supporting TOGA and advancing life-saving lung cancer research.
Dr Wasek Faisal, Dr Vanessa Brunelli, Dr Tracy Leong, Dr Lara Edbrooke, Dr Peter Shi
Empowering Discovery: An Update on the 2024 Inspirational Research Grant Projects
We are excited about awarding new grants but first, we check in on progress made by our 2024 recipients....
ASPiRATION schema showing progression from study entry to genomic testing in conjunction with standard of care testing, to results interpretation, and access to treatments.
Precision Medicine in Practice: How Genomic Data Shaped Australian Lung Cancer Policy
Learn how TOGA’s ASPiRATION study led to Medicare-funded genomic testing for lung cancer and national best practice guidelines in Australia.
Cancer Care for Older People: Evidence, Tools, and Practical Approaches
Optimise cancer care for older Adults with practical tips and tools to implement person-centred geriatric oncology.
DYNAMALK Clinical Trial: Dynamic Molecular Profiling in ALK-Positive Lung Cancer
DYNAMALK is a significant clinical trial investigating the potential of comprehensive genomic profiling to revolutionise the treatment of ALK+ Non-Small Cell Lung Cancer (NSCLC)
A flow diagram showing the steps in liquid biopsy compared to tissue biopsy in obtaining genetic information to guide lung cancer treatment.
The Power of Liquid Biopsy: A New Frontier in Cancer Care
Liquid biopsy is revolutionising lung cancer care by using a blood test to examine the tumour without the need for a lung biopsy.
OCEANIC clinical trial schema
OCEANiC clinical trial: Optimising Adjuvant Therapy in Early-Stage EGFR-Mutant Lung Cancer
OCEANiC will determine if patients with resected stage II to IIIA EGFR mutant NSCLC require intensification of osimertinib monotherapy with chemotherapy.
SHERLOCK Clinical Trial: Promising First-Line Results for KRAS G12C-Mutated Lung Cancer
Latest results from the SHERLOCK clinical trial show promising first-line outcomes for patients with KRAS G12C-mutated lung cancer, combining sotorasib with chemotherapy and bevacizumab.
Scientific Committee Meeting with pen and notepad
TOGA’s Scientific Committee Meeting Recap – August 2025
A re-cap of the Scientific Committee meeting in August 2025 and the year to date.
Join our community – stay up to date with the latest research, TOGA news and events

The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.

Contact

PO Box 1103
Thornbury VIC 3071
Ph: +61 3 9087 3550
ABN: 47 641 984 198

Facebook-f X-twitter Linkedin-in Instagram Podcast
TOGA
Quicklinks
TOGA is an ACNC Registered Charity

Thoracic Oncology Group of Australasia is registered with the Australian Taxation Office as an Income Tax Exempt Charitable Entity. Donations $2 and over are tax deductible.

Copyright © 2026 TOGA – Thoracic Oncology Group Australasia. No part of this site may be reproduced without our written permission.